Gout common medicine soared six times in three years. Patients can't afford to take medicine and plan to cut their feet

The price of commonly used drugs is soaring In March 2018, a patient reported on Jingmen news online: "I am a gout patient, and allopurinol tablet is the basic drug for gout treatment Since 2010, I have taken allopurinol tablet orally, the price of which is from the initial 6.5 yuan 100 tablets, to 15 yuan 100 tablets in 2013, to more than 20 yuan 100 tablets in 2016, 37 yuan 100 tablets in the second half of 2017, and 72 yuan 100 tablets in the beginning of 2018 During this period, the relevant departments of the state have paid close attention to Jiangsu Province World Trade Tianjie and other three pharmaceutical companies collude with each other to impose huge penalties for monopoly price hikes, and now they are soaring again Is it illegal? Hope to check " Liu Ye (pseudonym), the head of a drugstore in Sichuan Province, confirmed to the reporter of China Business Daily: "at present, the purchase price of 100 allopurinol tablets has skyrocketed to more than 130 yuan, and the price of the same 100 digoxin tablets has risen from about 10 yuan to about 70-80 yuan, and now it is down to more than 60 yuan." It is strange that, on the one hand, the market price of allopurinol tablets has skyrocketed, on the other hand, there are few enterprises producing allopurinol tablets At present, there are 16 manufacturers holding allopurinol tablet drug approval, and 1 manufacturer holding allopurinol sustained release capsule and allopurinol sustained release tablet drug approval respectively Our reporter contacted many manufacturers of allopurinol tablets and found that due to the "one drug is hard to find", only a few enterprises are producing the drug ▌ the price has skyrocketed several times It is understood that allopurinol tablets are commonly used in the treatment of hyperuricemia and other diseases According to the data of mienei.com, in the terminal anti gout drug market of public hospitals in key provinces and cities in 2018, non busstat accounted for 73.12% of the market share, benzbromarone accounted for 19.31%, allopurinol tablets accounted for 7.14%, colchicine accounted for 0.44% The reporter searched in tmall medical center and found that the manufacturers of allopurinol tablets currently on display and sale mainly include Guangzhou Kanghe Pharmaceutical Co., Ltd., Hefei Jiulian Pharmaceutical Co., Ltd and Guangdong bidi Pharmaceutical Co., Ltd the price of 100 allopurinol tablets is generally above 170 yuan The staff of zhizhentang pharmacy in Fangshan District of Beijing told reporters that allopurinol tablets had been out of stock for a long time, and the price of 20 allopurinol tablets was 36 yuan "At present, allopurinol tablets are not available, only allopurinol sustained-release capsules from a pharmaceutical company in Heilongjiang Province are still on sale," a staff member of a jiashitang drugstore in Beijing told reporters The general manager of a large chain drugstore in Shenyang told reporters that it is very common for drug prices to skyrocket Due to its earlier purchase time, the current sales price of allopurinol tablets in its drugstore is more than 40 yuan, but now the purchase price of the drug is also more than 100 yuan Liu Ye introduced to the reporter that at present, the purchase price of 100 allopurinol tablets has skyrocketed from more than 20 yuan two years ago to more than 130 yuan When the price is high, it will reach 150 yuan, and all major pharmaceutical companies are out of stock Our reporter noted that the sharp rise in the price of allopurinol tablets has caused great repercussions in many social platforms and political and civil communication platforms According to the information on drug price website 315, users have a strong response to the continuous increase in the price of allopurinol tablets On February 9, 2019, a user left a message saying: "remember that the price of a bottle of 100 tablets was more than 10 yuan the year before last Last year, it was more than 30 yuan This year, it has increased from more than 80 yuan to more than 100 yuan!"! It may be that there are more people who buy less goods, and the output will fall down later At present, it's too high Someone should take care of it! " On the online public voice forum of Jiaodong online, on December 25, 2018, some netizens reported: "allopurinol tablets, as the first choice of national basic drugs for gout treatment, rose to 200 yuan from 5 yuan a bottle in 2015, and there are no goods in every drugstore in Yantai Those who have goods are also dead and expensive Does the government care? So it's been out of stock and up? " In addition to pharmacies, the bid price of allopurinol tablets in hospitals has also increased significantly According to the database information of yaozhi.com, in 2017, the highest bid price of allopurinol tablets (0.1g × 100) was 83.1 yuan, with an average bid price of 39.78 yuan By 2019, the average bidding price of allopurinol tablets was 97.5 yuan On the drug terminal network, which provides drugstores with purchase channels, the reporter noted that only allopurinol tablets of Hefei Jiulian Pharmaceutical Co., Ltd (hereinafter referred to as "Hefei Jiulian pharmaceutical") are on sale The company's staff told reporters that although the production of allopurinol tablets, but the volume is relatively small, mainly because of the shortage of raw materials "If you want to buy allopurinol tablets, you can only contact the local pharmacy or pharmaceutical company to let them come to the company for purchase," the staff told reporters In addition, the reporter also contacted a number of enterprises producing allopurinol tablets Guangzhou Kanghe Pharmaceutical Co., Ltd staff told reporters that allopurinol tablets are no longer produced because there is no API The staff of Shanghai Xinyi Vientiane Pharmaceutical Co., Ltd said: "if you can't buy it, you don't do it This is generally the case." ▌ only two enterprises produce APIs According to the data disclosed by minenet, in 2018, the amount of allopurinol used in public hospitals in key provinces and cities was 30.71 million yuan, down 1.52% year on year In clinical use, 76.85% of them were capsule and 23.15% were tablet The bidding price of allopurinol sustained-release capsule (0.25g × 10) is more than 30 yuan The top five enterprises in allopurinol drug market are Heilongjiang Aolida nede Pharmaceutical Co., Ltd (hereinafter referred to as "Aolida nede Pharmaceutical Co., Ltd.) Relying on the exclusive product allopurinol sustained-release capsule, they occupy 76.84% of the market share, Shanghai Shangyao Xinyi occupies 13.48%, Jiangsu Shimao Tianjie occupies 5.92%, Guangdong bidi occupies 1.82%, Guangzhou Kanghe occupies 1.78%, Hefei Jiulian pharmaceutical and Chongqing Qingyang Pharmaceutical Co., Ltd Limited company (hereinafter referred to as "Chongqing Qingyang") and other companies have a small share According to the database information of the State Food and drug administration, at present, there are 6 manufacturers holding allopurinol API approval documents However, up to now, only two enterprises remain in the validity period of allopurinol API GMP certificate, namely Heilongjiang mazhilun Pharmaceutical Co., Ltd (hereinafter referred to as "mazhilun pharmaceutical") and Chongqing Southwest Synthetic Pharmaceutical Co., Ltd (hereinafter referred to as "Southwest synthetic pharmaceutical") According to enterprise business information, McLaren pharmaceutical used to be a 90% direct holding subsidiary of aolidanide pharmaceutical On November 1, 2018, Aolida nede Pharmaceutical Co., Ltd withdrew from the shareholders of McLaren Pharmaceutical Co., Ltd Zhou Youjun obtained 90% equity of McLaren Pharmaceutical Co., Ltd According to qixinbao data, McLaren pharmaceutical is still an associated enterprise of aolidanide pharmaceutical In addition, the industrial and commercial information of the enterprise shows that southwest Synthetic Pharmaceutical Co., Ltd is the holding subsidiary of Peking University Medical Industry Group Co., Ltd As for the shortage of APIs reported by several allopurinol tablet manufacturers, our reporter, as a purchaser, respectively, called mazzlon pharmaceutical and southwest synthetic pharmaceutical for verification The company said that its allopurinol APIs are only supplied to aolidanide, with a relatively small production volume and are not sold to the outside world This means that, in addition to the API provided by McLaren to aolidanide, other manufacturers of allopurinol tablets are waiting for the "next pot" of allopurinol API of Southwest synthetic pharmaceutical As long as the supply of Southwest synthetic pharmaceutical is stopped, the downstream pharmaceutical enterprises will be forced to stop production, and the market will be monopolized by aolidanide pharmaceutical However, the reporter of our newspaper has been tossing and turning for many times and failed to contact southwest synthetic pharmaceutical ▌ before the market called for "tangible hand", some readers reported to our reporter: "my gout drug allopurinol rose from the initial 8.9 yuan to 116 yuan, with a time difference of less than 5 years I plan to cut off my foot and can't afford medicine National government departments say it's market pricing and they don't take care of it " In fact, as early as January 2016, the national development and Reform Commission has imposed penalties on the case of monopoly agreement of allopurinol tablets, and the punishment of market monopoly of allopurinol APIs also has a precedent In January 2016, the national development and Reform Commission announced that in response to the monopoly agreements reached by Chongqing Qingyang and its dealers Chongqing Datong, Jiangsu World Trade Tianjie, Shanghai Xinyi united and its dealer Shangqiu Huajie, the national development and Reform Commission imposed a total fine of 3995400 yuan on allopurinol tablets In addition, in October 2015, Chongqing Administration of industry and Commerce imposed a penalty of 439300 yuan on Chongqing Qingyang allopurinol API market monopoly In November 2017, in order to further regulate the market price behavior of short drugs and APIs, maintain the market price order, establish a market environment for fair competition in the purchase and sale of drugs and APIs, and protect the interests of consumers, the national development and Reform Commission studied and published the guide for price behavior of short drugs and API operators, and proposed eight price laws for short drugs and API operators Prohibited acts Article 47 of the antimonopoly law stipulates that if an operator violates the provisions of this Law and abuses its dominant position in the market, the antimonopoly law enforcement agency shall order it to stop the illegal act, confiscate its illegal income and impose a fine of not less than 1% but not more than 10% of the sales volume of the previous year However, can the fine of 1% - 10% of the sales volume in the previous year have a real deterrent effect on some pharmaceutical enterprises that monopolize the market? Liu Ye, the head of the Sichuan drugstore, said: "a fine of several million yuan is too small." "The price of drugs has skyrocketed It's not clear whether it's due to the rise of raw materials or artificial manipulation However, as far as I know, some enterprises will monopolize the market through M & A or payment of certain fees " Liu Ye told reporters To this end, Deng Yong, associate professor of medicine and health law in the law department of Beijing University of traditional Chinese medicine, pointed out to our reporter: "from the perspective of the amount of punishment in the national anti monopoly law, it is not enough to impose a fine of 1% - 10% of the sales volume of the previous year on the violator The penalty for the violators is disproportionate or mismatched to the benefits of their monopoly It is suggested that in addition to economic punishment, other measures should be taken to combine the offenders who abuse the dominant position of API Market to create a fair market environment and protect the legitimate rights and interests of patients " In fact, in recent years, amoxicillin, Hypotensive No.0, metronidazole, terramycin, virin, and dysterone, which are effective and low-cost, have increased their prices several times or even dozens of times, and the number of drugs whose prices have skyrocketed has reached as many as 100 The market calls for the intervention of "tangible hand".